Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases (MAG1C)
Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases: A Randomised, Placebo-controlled Trial
Sponsor: Filip Krag Knop
This PHASE2 trial investigates Diabetes Mellitus, Type 1 and is currently completed. Filip Krag Knop leads this study, which shows 10 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Jun 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE2
-
Apr 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Feb 2019 — Apr 2019 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Filip Krag Knop
- Steno Diabetes Center Copenhagen
For direct contact, visit the study record on ClinicalTrials.gov .